Compare Deckers Outdoor Corp (DECK) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Novartis AG — how do they compare? Deckers Outdoor Corp trades at $82.9 (market cap $11.24B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 23.9× Deckers Outdoor Corp's market cap, and Novartis AG pays a 3.31% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Novartis AG for 82 Days on average.
| DECK | NVS | |
|---|---|---|
Market Cap | $11.24B | $268.57B |
Volume | 3,010,945 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $168.62 |
52-Week Low | $77.51 | $121.80 |
Typical Hold Time | 71 Days | 82 Days |
Enterprise Value | $10.11B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.89, up 3.12% recently, with a bullish technical signal and strong fundamental performance. The stock shows robust revenue growth from $3.2B in 2022 to $5.0B in 2025, with net income rising to $966M. Key brands HOKA and UGG drive momentum, supported by positive analyst sentiment and a consensus price target of $117.13. Cash flow remains healthy, though 2026 projections indicate a net cash outflow.
The outlook for DECK is positive, with earnings beats and brand strength offering upside potential. Risks include competitive pressures in footwear and reliance on key brands. Analyst consensus leans bullish, but investors should monitor execution and market volatility.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
